QLT to sell off Aczone following FDA decision

VANCOUVER, Canada QLT has announced that it will proceed with its plan to sell its topical acne treatment Aczone after the Food and Drug Administration removed key blood monitoring requirements for the treatment, according to Reuters.

The company is selling the drug as part of a multi-step process to return it to its core business of treating eye diseases. Recently the company had been delving into acne and prostate cancer treatments.

Already several companies have expressed interest in Aczone and QLT predicts the drug will be sold within the next quarter or two.